Dr Alison J Butt
Senior Research Officer; Group leader, Apoptosis Research Group, Cancer Program, Garvan Institute of Medical Research; Cancer Institute NSW Fellow; Conjoint Senior Lecturer, Faculty of Medicine, The University of New South Wales; Director, Australian Society for Medical Research National Board
Email: a.butt 'at' garvan.org.au
Research Group: Apoptosis
Education
1996 PhD University of Bristol, UK
1992 BSc (Hons) University of Nottingham, UK
Publications
Millar EKA, LR Anderson, CM McNeil, SA O'Toole, M Pinese, P Crea, A Morey, AV Biankin, SM Henshall, EA Musgrove, RL Sutherland & AJ Butt (2009) BAG-1 predicts patient outcome and tamoxifen responsiveness in ER-positive invasive ductal carcinoma of the breast. Brit J Cancer 100: 123-33
Butt AJ, CM Sergio, CK Inman, LR Anderson, CM McNeil, AJ Russell, M Nousch, T Preiss, AV Biankin, RL Sutherland & EA Musgrove (2008) The estrogen- and c-Myc-target gene, HSPC111, is overexpressed in breast cancer and associated with poor patient outcome.
Breast Cancer Res: 10: R28
Butt AJ, RL Sutherland & EA Musgrove (2007) Live or let die: Oestrogen regulation of survival signalling in endocrine response. Breast Cancer Res. 9 (5): 306
Roberts CG, E Gurisik, TJ Biden, RL Sutherland & AJ Butt (2007) Synergistic cytotoxicity between tamoxifen and the plant toxin, persin, in human breast cancer cells is dependent upon Bim expression and mediated by modulation of ceramide metabolism. Mol. Cancer Ther. 6 (10): 2777-85
Butt AJ, Roberts CG, Seawright AA, Oelrichs PB, MacLeod JK, Liaw TYE, Kavallaris M, Somers-Edgar TJ, Lehrbach GM, Watts CK, Sutherland RL. A novel plant toxin, persin, with in vivo activity in the mammary gland, induces Bim-dependent apoptosis in human breast cancer cells. Mol Cancer Ther 2006; 5:2300-2309.
Butt AJ, McNeil CM, Musgrove EA, Sutherland RL. Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E. Endocr Relat Cancer 2005; 12(Supplement_1):S47-S59.
Butt AJ, Dickson KA, Jambazov S, Baxter RC. Enhancement of tumor necrosis factor alpha-induced growth inhibition by insulin-like growth factor binding protein (IGFBP)-5 but not IGFBP-3 in human breast cancer cells. Endocrinology 2005; 146: 3113-22
Butt AJ, Martin JL, Dickson KA, McDougall F, Firth SM, Baxter RC. Insulin-like growth factor binding protein-3 expression is associated with growth stimulation of T47D human breast cancer cells: the role of altered epidermal growth factor signalling. J Clin Endocrinol Metab 2004; 89:1950-1956.
Butt AJ, Dickson KA, McDougall F, Baxter RC. Insulin-like growth factor binding protein-5 inhibits the growth of human breast cancer cells in vitro and in vivo. J Biol Chem 2003; 278: 29676-85
Butt AJ, Fraley KA, Firth SM, Baxter RC. Insulin-like growth factor binding protein-3-induced growth inhibition and apoptosis do not require cell-surface binding and nuclear translocation in human breast cancer cells. Endocrinology 2002; 143: 2693-9
